Basic pharmacokinetics (2012)

Basic Pharmacokinetics



Basic Pharmacokinetics
SECOND EDITION
Sunil S. Jambhekar BPharm, MS, PhD
Professor and Associate Dean, LECOM-Bradenton, School of Pharmacy, Bradenton, Florida, USA
Philip J. Breen PhD
Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy,
University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

London • Philadelphia


Published by Pharmaceutical Press
1 Lambeth High Street, London SE1 7JN, UK
University City Science Center, Suite 5E,
3624 Market Street, Philadelphia, PA 19104,
USA
c Royal Pharmaceutical Society of Great Britain 2012
is a trade mark of Pharmaceutical Press
Pharmaceutical Press is the publishing division of the
Royal Pharmaceutical Society
First edition published 2009
Second edition published 2012
Typeset by River Valley Technologies, India
Printed in Great Britain by TJ International, Padstow, Cornwall
ISBN 978 0 85369 980 4
All rights reserved. No part of this publication may be reproduced,

stored in a retrieval system, or transmitted in any form or by any means,
without the prior written permission of the copyright holder.
The publisher makes no representation, express or implied,
with regard to the accuracy of the information contained in this book
and cannot accept any legal responsibility or liability for any errors or
omissions that may be made.
The right of Sunil S. Jambhekar and Philip J. Breen to be identified as the authors of this
work has been asserted by them in accordance with the Copyright,
Designs and Patents Act, 1988.
A catalogue record for this book is available from the British Library.


Contents

Preface
About the authors
1

Introduction and overview
1.1
1.2
1.3
1.4
1.5
1.6

2

3

Use of drugs in disease states
Important definitions and descriptions
Sites of drug administration
Review of ADME processes
Pharmacokinetic models
Rate processes

xi
xiii
1
1
2
4
5
7
12

Mathematical review

17

2.1
2.2
2.3
2.4
2.5
2.6
2.7
2.8
2.9

2.10

17
18
18
18
19
20
21
21
24
25

Introduction
A brief history of pharmacokinetics
Hierarchy of algebraic operations
Exponents and logarithms
Variables, constants, and parameters
Significant figures
Units and their manipulation
Slopes, rates, and derivatives
Time expressions
Construction of pharmacokinetic sketches (profiles)

Intravenous bolus administration (one-compartment model)

29

3.1
3.2

3.3
3.4
3.5
3.6
3.7
3.8
3.9

29
30
32
36
38
40
41
42
43

Introduction
Useful pharmacokinetic parameters
The apparent volume of distribution (V)
The elimination half life (t1/2 )
The elimination rate constant (K or Kel )
Plotting drug concentration versus time
Intravenous bolus administration of drugs: summary
Intravenous bolus administration: monitoring drug in urine
Use of urinary excretion data


vi

4

5

6

Contents

Clearance concepts

55

4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9

Introduction
Clearance definitions
Clearance: rate and concentration
Clearance: tank and faucet analogy
Organ clearance
Physiological approach to clearance
Estimation of systemic clearance

Calculating renal clearance (Clr ) and metabolic clearance (Clm )
Determination of the area under the plasma concentration versus time curve:
application of the trapezoidal rule
4.10 Elimination mechanism
4.11 Use of creatinine clearance to determine renal function
Appendix: Recently developed equations for estimating creatinine clearance and
glomerular filtration rate

55
56
58
58
60
61
65
66
67

Problem set 1

79

Drug absorption from the gastrointestinal tract

95

5.1
5.2
5.3
5.4

95
98
100
101

Extravascular routes of drug administration
6.1
6.2
6.3
6.4
6.5
6.6
6.7
6.8
6.9
6.10
6.11
6.12
6.13

7

Gastrointestinal tract
Mechanism of drug absorption
Factors affecting passive drug absorption
pH–partition theory of drug absorption

Introduction
Drug remaining to be absorbed, or drug remaining at the site of administration

Determination of elimination half life (t1/2 ) and elimination rate constant (K or Kel )
Absorption rate constant (Ka )
Wagner–Nelson method (one-compartment model) and Loo–Riegelman method
(two-compartment model)
Lag time (t0 )
Some important comments on the absorption rate constant
The apparent volume of distribution (V)
Time of maximum drug concentration, peak time (tmax )
Maximum (peak) plasma concentration (Cp )max
Some general comments
Example for extravascular route of drug administration
Flip-flop kinetics

69
69
76

105
106
106
109
110
111
115
116
116
117
118
120
121

126

Problem set 2

127

Bioavailability/bioequivalence

137

7.1
7.2
7.3

Introduction
Important definitions
Types of bioavailability

138
138
139


Contents

7.4
7.5
7.6
7.7
7.8

7.9

7.10
7.11
7.12
7.13

8

157
157
158
159

Factors affecting drug absorption: Physicochemical factors

175

Dissolution rate
Dissolution process
Noyes–Whitney equation and drug dissolution
Factors affecting the dissolution rate

Gastrointestinal absorption: Role of the dosage form
Introduction
Solution (elixir, syrup, and solution) as a dosage form
Suspension as a dosage form
Capsule as a dosage form
Tablet as a dosage form
Dissolution methods

Formulation and processing factors
Correlation of in vivo data with in vitro dissolution data

Continuous intravenous infusion (one-compartment model)
10.1
10.2
10.3
10.4
10.5

Introduction
Monitoring drug in the body or blood (plasma/serum)
Sampling drug in body or blood during infusion
Sampling blood following cessation of infusion
Use of post-infusion plasma concentration data to obtain half life, elimination rate
constant and the apparent volume of distribution
10.6 Rowland and Tozer method

11

145
155

161

9.1
9.2
9.3
9.4
9.5

9.6
9.7
9.8

10

141
141
142
143

Problem set 3

8.1
8.2
8.3
8.4

9

Bioequivalence
Factors affecting bioavailability
The first-pass effect (presystemic clearance)
Determination of the area under the plasma concentration–time curve and the
cumulative amount of drug eliminated in urine
Methods and criteria for bioavailability testing
Characterizing drug absorption from plasma concentration versus time and from urinary
data following the administration of a drug via different extravascular routes and/or
dosage forms
Equivalency terms

Food and Drug Administration codes
Fallacies on bioequivalence
Evidence of generic bioinequivalence or of therapeutic inequivalence for certain
formulations approved by the FDA

vii

175
175
176
177

187
187
188
188
189
189
191
191
194

203
203
205
205
220
222
225

Problem set 4

227

Multiple dosing: Intravenous bolus administration

237

11.1 Introduction
11.2 Useful pharmacokinetic parameters in multiple dosing

237
241


viii

Contents

11.3
11.4
11.5
11.6
11.7
11.8

12

Multiple dosing: extravascular routes of drug administration
12.1

12.2
12.3
12.4
12.5
12.6
12.7
12.8
12.9
12.10

13

Introduction
The peak time in multiple dosing to steady state (tmax )
Maximum plasma concentration at steady state
Minimum plasma concentration at steady state
‘‘Average’’ plasma concentration at steady state: extravascular route
Determination of drug accumulation: extravascular route
Calculation of fluctuation factor ( ) for multiple extravascular dosing
Number of doses required to reach a fraction of steady state: extravascular route
Determination of loading and maintenance dose: extravascular route
Interconversion between loading, maintenance, oral, and intravenous bolus doses

248
249
251
254
254
255

257
257
259
260
261
262
263
264
264
265
266

Problem set 5

271

Two-compartment model

285

13.1
13.2
13.3
13.4
13.5
13.6
13.7
13.8
13.9
13.10

13.11

14

Designing or establishing the dosage regimen for a drug
Concept of drug accumulation in the body (R)
Determination of fluctuation ( ): intravenous bolus administration
Number of doses required to reach a fraction of the steady-state condition
Calculation of loading and maintenance doses
Maximum and minimum drug concentration at steady state

Introduction
Intravenous bolus administration: two-compartment model
Determination of the post-distribution rate constant (β) and the coefficient B
Determination of the distribution rate constant (α) and the coefficient A
Determination of micro rate constants: the inter-compartmental rate constants
(K21 and K12 ) and the pure elimination rate constant (K10 )
Determination of volumes of distribution (V)
How to obtain the area under the plasma concentration–time curve from time zero to
time t and time ∞
General comments
Example
Further calculations to perform and determine the answers
Extravascular dosing of a two-compartment model drug

285
287
292
292
295

296
298
299
300
302
303

Problem set 6

305

Multiple intermittent infusions

309

14.1 Introduction
14.2 Drug concentration guidelines
14.3 Example: determination of a multiple intermittent infusion dosing regimen for an
aminoglycoside antibiotic
14.4 Dose to the patient from a multiple intermittent infusion
14.5 Multiple intermittent infusion of a two-compartment drug: vancomycin ‘‘peak’’ at 1 hour
post infusion

309
311
311
313
313

Contents

14.6 Vancomycin dosing regimen problem
14.7 Adjustment for early or late drug concentrations

15

319

Nonlinear pharmacokinetics

323

Introduction
Capacity-limited metabolism
Estimation of Michaelis–Menten parameters (Vmax and Km )
Relationship between the area under the plasma concentration versus time curve and
the administered dose
15.5 Time to reach a given fraction of steady state
15.6 Example: calculation of parameters for phenytoin

Drug interactions

341

Introduction
The effect of protein-binding interactions
The effect of tissue-binding interactions
Cytochrome P450-based drug interactions
Drug interactions linked to transporters

341
342
348
349
355

Problem set 9

357

Pharmacokinetic and pharmacodynamic relationships

359
359
361
364

Problem set 10

367

Metabolite pharmacokinetics

369

18.1
18.2
18.3
18.4

18.5
18.6
18.7
18.8
18.9
18.10
18.11

19

332
333

337

17.1 Introduction
17.2 Generation of a pharmacokinetic– pharmacodynamic (PKPD) equation
17.3 Pharmacokinetic and pharmacodynamic drug interactions

18

323
325
327
330

Problem set 8

16.1
16.2

16.3
16.4
16.5

17

314
315

Problem set 7

15.1
15.2
15.3
15.4

16

ix

Introduction
General model
Single intravenous bolus of drug conforming to a one-compartment model
Single oral dose of drug conforming to a one-compartment model
Intravenous infusion of a one-compartment model parent drug
Chronic dosing to steady state
Study design required to obtain various metabolite pharmacokinetic parameters
Computer-aided simulation and fitting of metabolite pharmacokinetic data
Case in point: meperidine and normeperidine
Active metabolites in renal dysfunction

Sample metabolite pharmacokinetics calculations

Pharmacokinetic data fitting
19.1 Introduction
19.2 Pharmacokinetic parameter determination

369
370
370
382
384
385
388
388
388
388
393

395
395
395


x

Contents

19.3
19.4
19.5

19.6
19.7
19.8
19.9
19.10
19.11
19.12

20

Nonlinear regression
Goodness of fit indices
Ways to improve fit
Evaluation of program output
How are the values of the parameters determined?
Problems that may occur during a nonlinear regression run
Weighting of data points
Simulation
Initial estimates
Conclusion

Pharmacokinetics and pharmacodynamics of biotechnology drugs
20.1
20.2
20.3
20.4
20.5
20.6

Introduction

Proteins and peptides
Monoclonal antibodies
Oligonucleotides
Vaccines (immunotherapy)
Gene therapies

Appendix: Statistical moment theory in pharmacokinetics
A.1
A.2
A.3

Glossary
References
Index

Introduction
Statistical moment theory
Applications

397
398
401
401
404
407
408
409
411
412

413
413
413
419
423
424
425

427
427
428
439

443
453
461


Preface

Pharmacokinetics and biopharmaceutics courses have
been included in pharmacy curricula across the
United States and in many other countries for the
past several years. At present, there are a number
of textbooks available for use by students and other
readers. Most of these textbooks, although valuable
and well written, concentrate on presenting the material in substantial mathematical depth, with much less
needed emphasis on explanations which will facilitate
understanding and the ability to use the pharmacokinetic equations that are introduced. Furthermore,
also evident in currently available textbooks is a

paucity of adequate explanation regarding factors
influencing pharmacokinetic parameters present in
these equations.
The intent of this textbook is to provide the reader
with a basic intuitive understanding of the principles
of pharmacokinetics and biopharmaceutics and how
these principles, along with the equations presented
in each chapter, can be applied to achieve successful drug therapy. It has been our intent to illustrate
the application of pharmacokinetic principles and
equations by providing the reader with data available in the literature. Additionally, when relevant,
problem sets and problem-solving exercises, complete
with keys, have been provided at the conclusion of
each chapter. This approach will enable the reader to
become adept at solving pharmacokinetic problems
arising in drug therapy and to understand the applications and utility of equations in clinical practice.
Since pharmacokinetics is basically mathematical
in nature, a chapter has been included to provide the
reader with a basic review of the mathematical principles and graphing techniques necessary to understand pharmacokinetics. At the outset of each chapter,
important objectives have been listed that will accentuate and identify the salient and indelible points

of the chapter. When an important and clinically
applicable equation appears in the text, a paragraph
follows explaining the significance and therapeutic
applications of the equation. Additionally, this paragraph includes and explains the relevant factors which
influence the parameters appearing in an equation.
After the introduction of an important equation, a
general profile illustrating the relationship between
the two variables of an equation has been presented.
This approach, we believe, will demystify key concepts in pharmacokinetics.
Derivations of key equations have been included

to show their origins and to satisfy the inquisitive
student. However, the student is not required to memorize any of these derivations or to be able to perform
them in any problem set or problem solving exercise.

Topics added since the first edition
New chapters on Metabolite Pharmacokinetics
(Chapter 18) and Pharmacokinetic Data Fitting
(Chapter 19) have been added. The former chapter
recognizes that, as more and more pro-drugs are marketed, the need to understand the pharmacokinetics
of the active metabolites arising becomes important.
The latter chapter allows the interested reader to
“peek under the hood” and observe the inner workings of the type of nonlinear regression program used
to create pharmacokinetic parameters from pharmacokinetic data. Additionally, an Appendix delineating
some of the more recent methods for the estimation of creatinine clearance has been added to the
end of Chapter 4. A discussion of the Wagner and
Nelson method for the determination of the absorption rate constant using urinary data analysis following the administration of a drug by an extravascular route has been included in Chapter 6. A section


xii

Preface

on two-compartment model pharmacokinetics for an
extravascularly administered drug has been added to
Chapter 13.
Tables 20.2 (Monoclonal antibody therapeutics
in current use) and 20.3 (Gene therapy products
under development) have been updated. The question database has been expanded to include multiple
choice questions and true/false questions, as well as
a large increase in the number of questions based on

pharmacokinetic profiles (sketches). This latter addition is to afford the reader a deeper understanding
of the relationships among variables and parameters
undergirding pharmacokinetic equations.

Organization
As listed in the table of contents, the book is organized into twenty chapters, as well as an Appendix
devoted to statistical moment theory and its applications in pharmacokinetics. The first chapter consists
of an introduction to the principles necessary to understand pharmacokinetics as well as an overview of
the subject matter. The remaining chapters are organized in an order which should be easy for the reader
to follow, while still demonstrating the salient features
of each topic. Clearance and other essential fundamental pharmacokinetic parameters have been introduced early in the book, since the student will need to
apply these concepts in subsequent chapters. This has

necessitated cross referencing concepts introduced in
the first few chapters throughout the remainder of the
book.
We have adopted a uniform set of notation
throughout the textbook. This notation has been defined within the body of the book and also summarized in two glossaries at the end of the book.
Since the text is primarily targeted for the entry
level pharmacy (Pharm.D.) students in the United
States and Canada, the book fulfills the current course
requirements of schools of pharmacy in those countries. In addition, we believe that the book will prove
to be of considerable value and utility for pharmaceutical scientists with no formal pharmacy education,
medical students, graduate students in the pharmaceutical sciences, as well as for undergraduate and
graduate students in the United States, in the United
Kingdom, and in countries where the medium of instruction in colleges of pharmacy is English.
In conclusion, we wish to acknowledge our mentors, colleagues, and a number of former and current diligent and serious undergraduate and graduate
students for their constructive comments, encouragement, suggestions, and support. We view them as
partners in our quest to facilitate understanding of
pharmacokinetics.

Sunil S. Jambhekar
Philip J. Breen
October 2011


About the authors

Sunil S. Jambhekar received his BPharm degree from
Gujarat University, India and MS and PhD degrees
in Pharmaceutics from the University of Nebraska.
Prior to pursuing graduate education, Dr Jambhekar
worked for four years as a research scientist at two
major pharmaceutical companies in India.
Prior to assuming his current position, Dr Jambhekar served as an Assistant and Associate Professor of Pharmaceutics at the Massachusetts College
of Pharmacy in Boston, where he was a recipient
of the Trustee’s Teacher of the Year award and the
Scholarly Publication award. Subsequently he was
appointed Professor of Pharmaceutics at South University School of Pharmacy in Savannah, Georgia.
Dr Jambhekar has taught undergraduate and
graduate courses in pharmaceutics and pharmacokinetics. Additionally, he has directed the research
and served on the thesis advisory committees of a
number of graduate students. He has authored many
peer-reviewed articles and book chapters as well as
scientific presentations at national and international
conferences. Dr Jambhekar has reviewed scientific
books and research articles for many journals. He has
been an invited external examiner for a number of

doctoral candidates at colleges of pharmacy here and
abroad.

Dr Jambhekar has been a Fulbright Scholar in
the lecture/research category for India and was a
Fulbright Senior Specialist and Fulbright Foundation
grantee in the global/public health category. Dr Jambhekar is an active member of several professional
organizations.
Philip J. Breen received his BS in Pharmacy and PhD
degrees at the Massachusetts College of Pharmacy
and Allied Health Sciences in Boston. For several
years between undergraduate and graduate school, he
was staff pharmacist and manager of a community
pharmacy. For the past 20 years, Dr Breen has been
Assistant and then Associate Professor at the College
of Pharmacy of the University of Arkansas for Medical Sciences in Little Rock, where he teaches courses
in both undergraduate and graduate pharmacokinetics. He was named Teacher of the Year at this college
in 1989 and a Teaching Scholar in 2009.
Dr Breen has numerous national presentations
and publications to his credit, as well as several
patents.


Dedication

To my parents
SSJ
To Ginny and Danny
PJB


1
Introduction and overview

1.1

Use of drugs in disease states

1

1.4

Review of ADME processes

5

1.2

Important definitions and descriptions

2

1.5

Pharmacokinetic models

7

1.3

Sites of drug administration

4

1.6

Rate processes

12

Objectives
Upon completion of this chapter, you will have the ability to:

• compare and contrast the terms pharmacokinetics and biopharmaceutics
• describe absorption, distribution, metabolism, and excretion (ADME) processes in pharmacokinetics

• delineate differences between intravascular and extravascular administration of drugs
• explain the compartmental model concept in pharmacokinetics
• explain what is meant by the order of a reaction and how the order defines the equation determining the rate of the reaction

• compare and contrast a first-order and a zero-order process.

1.1 Use of drugs in disease states
The use of drugs to treat or ameliorate disease goes
back to the dawn of history. Since drugs are xenobiotics, that is compounds that are foreign to the
body, they have the potential to cause harm rather
than healing, especially when they are used inappropriately or in the wrong dose for the individual
patient being treated. What, then, is the right dose?
The medieval physician/alchemist Paracelsus stated:
“Only the dose makes a thing not a poison.” This
implies: “The dose of a drug is enough but not too
much.” It is the objective of this text to present some
tools to allow the determination of the proper dose
— a dose that will be therapeutic but not toxic in

an individual patient, possessing a particular set of
physiological characteristics.
At the same time that the disciplines of medicine
and pharmacy strive to use existing drugs in the most

effective manner, scientific researchers are engaged in
the process of discovering new drugs that are safe
and effective and that are significant additions to our
armamentarium for the treatment or prevention of
disease. This process is increasingly time-consuming,
expensive, and often frustrating.
Here are two statistics about new drug approval:

•
•

the average time for a new drug to be approved
is between 7 and 9 years
the cost of introducing a new drug is approximately $700 million to $1 billion.

Steps involved in the drug development process
include:
1 The pharmacologically active molecule or drug
entity must be synthesized, isolated or extracted
from various possible sources (relying on the disciplines of medicinal chemistry, pharmacology,
and toxicology).


2

Basic Pharmacokinetics

2 The formulation of a dosage form (i.e., tablet,
capsules, suspension, etc.) of this drug must be
accomplished in a manner that will deliver a
recommended dose to the “site of action” or a
target tissue (employing the principles of physical pharmacy and pharmaceutics).
3 A dosage regimen (dose and dosing interval)
must be established to provide an effective concentration of a drug in the body, as determined
by physiological and therapeutic needs (utilizing
pharmacokinetics and biopharmaceutics).

The first such approach was made by Teorell
(1937), when he published his paper on distribution
of drugs. However, the major breakthrough in developing and defining this discipline has come since the
early 1970s.

Only a successful integration of these facets will
result in successful drug therapy. For example, an
analgesic drug with a high therapeutic range can be
of little use if it undergoes a rapid decomposition in
the gastrointestinal tract and/or it fails to reach the
general circulation and/or it is too irritating to be
administered parenterally.
Therefore, the final goal in the drug development
process is to develop an optimal dosage form to
achieve the desired therapeutic goals. The optimal
dosage form is defined as one that provides the maximum therapeutic effect with the least amount of drug
and achieves the best results consistently.
In other words, a large number of factors play an

important role in determining the activity of a drug
administered through a dosage form. It is one of the
objectives of this book to describe these factors and
their influence on the effectiveness of these drugs.
A variety of disciplines are involved in understanding the events that take place during the process
by which a chemical entity (substance) becomes an
active drug or a therapeutic agent.

“Pharmacokinetics is the study of kinetics of absorption, distribution, metabolism and excretion
(ADME) of drugs and their corresponding pharmacologic, therapeutic, or toxic responses in man and
animals” (American Pharmaceutical Association,
1972). Applications of pharmacokinetics studies include:

1 Principles of physics, physical chemistry, and
mathematics are essential in the formulation of
an optimum dosage form.
2 An understanding of physiology and pharmacology is essential in the process of screening for
active drug and in selecting an appropriate route
of administration.
3 Knowledge of the principles of kinetics (rate
processes), analytical chemistry, and therapeutics is essential in providing an effective concentration of a drug at the “site of action.”
Pharmacokinetics and biopharmaceutics are the
result of such a successful integration of the various
disciplines mentioned above.

1.2 Important definitions and
descriptions
Pharmacokinetics

•

•
•
•
•
•

bioavailability measurements
effects of physiological and pathological conditions on drug disposition and absorption
dosage adjustment of drugs in disease states, if
and when necessary
correlation of pharmacological responses with
administered doses
evaluation of drug interactions
clinical prediction: using pharmacokinetic parameters to individualize the drug dosing regimen and thus provide the most effective drug
therapy.

Note that in every case, the use must be preceded
by observations.

Biopharmaceutics
“Biopharmaceutics is the study of the factors influencing the bioavailability of a drug in man and animals
and the use of this information to optimize pharmacological and therapeutic activity of drug products” (American Pharmaceutical Association, 1972).
Examples of such factors include:

•
•

chemical nature of a drug (weak acid or weak
base)
inert excipients used in the formulation of a

dosage form (diluents, binding agents, disintegrating agents, coloring agents, etc.)


3

Introduction and overview

•

method of manufacture (dry granulation and/or
wet granulation)

•

physicochemical properties of drugs (pKa , particle size and size distribution, partition coefficient, polymorphism, etc.).

Generally, the goal of biopharmaceutical studies
is to develop a dosage form that will provide consistent bioavailability at a desirable rate. The importance of a consistent bioavailability can be very
well appreciated if a drug has a narrow therapeutic
range (e.g., digoxin) where small variations in blood
concentrations may result in toxic or subtherapeutic
concentrations.

Relationship between the administered
dose and amount of drug in the body
Only that fraction of the administered dose which actually reaches the systemic circulation will be available
to elicit a pharmacological effect.
For an intravenous solution, the amount of drug
that reaches general circulation is the dose administered. Moreover,
Dose = X0 = (AUC)∞

0 KV

constant, and V (or Vd ) is the drug’s volume of distribution.
Volume of distribution may be thought of as the
apparent volume into which a given mass of drug
would need to be diluted in order to give the observed
concentration.
For the extravascular route, the amount of drug
that reaches general circulation is the product of the
bioavailable fraction (F) and the dose administered.
Moreover,
F × Dose = FX0 = (AUC)∞
0 KV.

(1.2)

Equations (1.1) and (1.2) suggest that we must
know or determine all the parameters (i.e., (AUC)∞
0 ,
K, V, F) for a given drug; therefore, it is important to
know the concentration of a drug in blood (plasma
or serum) and/or the amount (mass) of drug removed
in urine (excretion data). A typical plasma concentration versus time profile (rectilinear, RL) following the
administration of a drug by an extravascular route is
presented in Fig. 1.1.

Onset of action
The time at which the administered drug reaches the
therapeutic range and begins to produce the effect.

(1.1)

where (AUC)∞
0 is the area under curve of plasma
drug concentration versus time (AUC) from time zero
to time infinity; K is the first-order elimination rate

Duration of action
The time span from the beginning of the onset of
action up to the termination of action.

MTC

Concentration ( µg mL–1)

Therapeutic range
MEC
Duration of
action
Termination
of action

Time (h)
Onset of action

Figure 1.1 A typical plot (rectilinear paper) of plasma concentration versus time following the administration of a drug by an
extravascular route. MTC, minimum toxic concentration; MEC, minimum effective concentration.


4

Basic Pharmacokinetics

Termination of action
The time at which the drug concentration in the
plasma falls below the minimum effective concentration (MEC).

1.3 Sites of drug administration
Sites of drug administration are classified into two
categories:

Therapeutic range
The plasma or serum concentration (e.g., µg mL−1 )
range within which the drug is likely to produce the
therapeutic activity or effect. Table 1.1 provides, as an
example, the therapeutic ranges of selected drugs.

One can monitor the drug in the urine in order to
obtain selected pharmacokinetic parameters of a drug
as well as other useful information such as the
bioavailability of a drug.

Table 1.1 The therapeutic ranges of selected drugs
Drug

Therapeutic use

Therapeutic range

Tobramycin

(Nebcin, Tobrex)

Bactericidal–antibiotic

4–8 mg L−1

Digoxin (Lanoxin)

Congestive heart
failure (CHF)

1–2 mg L−1

Carbamazepine
(Tegretol)

Anticonvulsant

4–12 mg L−1

Theophylline

Bronchial asthma

10–20 mg L−1

Cumulative amount of drug in urine (mg)

•
•

intravascular routes
extravascular routes.

Intravascular routes
Intravascular administration can be:

Amount of drug in the urine

•
•

intravenous
intra-arterial.

Important features of the intravascular route of
drug administration
1 There is no absorption phase.
2 There is immediate onset of action.
3 The entire administered dose is available to produce pharmacological effects.
4 This route is used more often in life-threatening
situations.
5 Adverse reactions are difficult to reverse or control; accuracy in calculations and administration
of drug dose, therefore, is very critical.
A typical plot of plasma and/or serum concentration against time, following the administration of the

10

(Xu)∞

9
8
7
6
5
4
3
2
1
0
0

Figure 1.2

Figure 1.2 represents a typical urinary plot,
regardless of the route of drug administration.

10

20

30

40

50
60
Time (h)

70

80

90

100

A typical plot (rectilinear paper) of the cumulative amount of drug in urine (Xu ) against time.


Introduction and overview

dose of a drug by intravascular route, is illustrated in
Fig. 1.3.

Extravascular routes of drug administration
Extravascular administration can be by a number of
routes:

•
•
•
•
•
•
•

oral administration (tablet, capsule, suspension,
etc.)
intramuscular administration (solution and suspension)

subcutaneous administration (solution and suspension)
sublingual or buccal administration (tablet)
rectal administration (suppository and enema)
transdermal drug delivery systems (patch)
inhalation (metered dose inhaler).

Important features of extravascular routes of
drug administration
1 An absorption phase is present.
2 The onset of action is determined by factors
such as formulation and type of dosage form,
route of administration, physicochemical properties of drugs and other physiological variables.
3 The entire administered dose of a drug may not
always reach the general circulation (i.e., incomplete absorption).

Concentration (µ g mL–1)

Figure 1.4 illustrates the importance of the
absorption characteristics when a drug is administered by an extravascular route.

5

In Fig. 1.4, note the differences in the onset of
action, the termination of action, and the duration of
action as a consequence of the differences in the absorption characteristics of a drug owing to formulation differences. One may observe similar differences
in the absorption characteristics of a drug when it is
administered via different dosage forms or different
extravascular routes.

1.4 Review of ADME processes

ADME is an acronym representing the pharmacokinetic processes of absorption, distribution,
metabolism, and elimination.

Absorption
Absorption is defined as the process by which a drug
proceeds from the site of administration to the site of
measurement (usually blood, plasma or serum).

Distribution
Distribution is the process of reversible transfer of
drug to and from the site of measurement (usually
blood or plasma). Any drug that leaves the site of
measurement and does not return has undergone
elimination. The rate and extent of drug distribution
is determined by:
1 how well the tissues and/or organs are perfused
with blood

Therapeutic
range

Drug A
Drug B

Time (h)

Figure 1.3 A typical plasma concentration versus time plot (rectilinear paper) following the administration of a dose of a drug
by an intravascular route.

6

Basic Pharmacokinetics

Concentration (µ g mL–1)

MTC

Absorption
phase

Formulation A

Therapeutic
range
MEC
Elimination phase
Formulation B
Formulation C

Time (h)

Figure 1.4 A typical plot (rectilinear paper) of plasma concentration versus time following the (oral) administration of an
identical dose of a drug via identical dosage form but different formulations. MTC, minimum toxic concentration; MEC, minimum
effective concentration.

propranolol HCl (Inderal) used as a nonselective β-antagonist: the active metabolite is
4-hydroxypropranolol
diazepam (Valium) used for symptomatic relief of
tension and anxiety: the active metabolite is

desmethyldiazepam.

2 the binding of drug to plasma proteins and
tissue components
3 the permeability of tissue membranes to the
drug molecule.
All these factors, in turn, are determined and controlled by the physicochemical properties and chemical structures (i.e., presence of functional groups) of
a drug molecule.

Metabolism
Metabolism is the process of a conversion of
one chemical species to another chemical species
(Fig. 1.5).
Usually, metabolites will possess little or none of
the activity of the parent drug. However, there are
exceptions. Some examples of drugs with therapeutically active metabolites are:
procainamide (Procan; Pronestyl) used as antidysrhythmic agent: the active metabolite is
N-acetylprocainamide

Aspirin
(acetylsalicylic
acid)

Figure 1.5
constant.

Km

Salicylic acid
Km3 Gentisic acid

(active)
(inactive)
Km1 Km2
Salicyluric
Salicyl
acid
glucuronide (inactive)
(inactive)

Metabolism of aspirin. Km , metabolic rate

Elimination
Elimination is the irreversible loss of drug from the
site of measurement (blood, serum, plasma). Elimination of drugs occur by one or both of:

•
•

metabolism
excretion.

Excretion
Excretion is defined as the irreversible loss of a drug
in a chemically unchanged or unaltered form. An
example is shown in Fig. 1.6.
The two principal organs responsible for drug
elimination are the kidney and the liver. The kidney
is the primary site for removal of a drug in a chemically unaltered or unchanged form (i.e., excretion)
as well as for metabolites. The liver is the primary
organ where drug metabolism occurs. The lungs, occasionally, may be an important route of elimination

for substances of high vapor pressure (i.e., gaseous
anesthetics, alcohol, etc.). Another potential route of
drug removal is via mother’s milk. Although not a significant route for elimination of a drug for the mother,
the drug may be consumed in sufficient quantity to
affect the infant.


Introduction and overview

Ku

Aspirin
(acetylsalicylic
acid)

Figure 1.6

Km

Kmu
Salicylic acid
(active)
Km3 Gentisic acid
(inactive)
Km1 Km2
Km3u
Salicyluric
Salicyl
acid (inactive) Km2u
glucuronide

(inactive)
Km1u

7

Unchanged
aspirin or
aspirin
metabolite in
urine:
Aspirin

Salicylic acid
Gentisic acid
Salicyluric acid
Salicyl
glucuronide

Renal excretion of aspirin and its metabolites. Km , metabolic rate constant.

Disposition
Once a drug is in the systemic circulation (immediately for intravenous administration and after the
absorption step in extravascular administration), it is
distributed simultaneously to all tissues including the
organ responsible for its elimination. The distinction
between elimination and distribution is often difficult.
When such a distinction is either not desired or is
difficult to obtain, disposition is the term used. In
other words, disposition is defined as all the processes
that occur subsequent to the absorption of the drug.

Hence, by definition, the components of the disposition phase are distribution and elimination.

1.5 Pharmacokinetic models
After administering a dose, the change in drug concentration in the body with time can be described
mathematically by various equations, most of which
incorporate exponential terms (i.e., ex or e−x ). This
suggests that ADME processes are “first-order” in
nature at therapeutic doses and, therefore, drug transfer in the body is possibly mediated by “passive diffusion.” Therefore, there is a directly proportional
relationship between the observed plasma concentration and/or the amount of drug eliminated in the
urine and the administered dose of the drug. This
direct proportionality between the observed plasma
concentration and the amount of drug eliminated
and the dose administered yields the term “linear
pharmacokinetics” (Fig. 1.7).

Concentrated
solution

Transfer

Region of low
concentration

Rate of transfer varies with the concentration
in the left compartment

Figure 1.7 The principle of passive diffusion and the
relationship between the rate of transfer and the
administered dose of a drug.

Because of the complexity of ADME processes,
an adequate description of the observations is sometimes possible only by assuming a simplified model;
the most useful model in pharmacokinetics is the
compartment model. The body is conceived to be
composed of mathematically interconnected compartments.

Compartment concept in
pharmacokinetics
The compartment concept is utilized in pharmacokinetics when it is necessary to describe the plasma
concentration versus time data adequately and accurately, which, in turn, permits us to obtain accurate
estimates of selected fundamental pharmacokinetics
parameters such as the apparent volume of drug distribution, the elimination half life, and the elimination rate constant of a drug. The knowledge of these
parameters and the selection of an appropriate equation constitute the basis for the calculation of the


8

Basic Pharmacokinetics

dosage regimen (dose and dosing interval) that will
provide the desired plasma concentration and duration of action for an administered drug.
The selection of a compartment model depends
solely upon the distribution characteristics of a drug
following its administration. The equation required
to characterize the plasma concentration versus time
data, however, depends upon the compartment model
chosen and the route of drug administration. The
selected model should be such that it will permit
accurate predictions in clinical situations. As mentioned above, the distribution characteristics of a
drug play a critical role in the model selection process. Generally, the slower the drug distribution in

the body, regardless of the route of administration,
the greater the number of compartments required
to characterize the plasma concentration versus time
data, the more complex is the nature of the equation employed. On the basis of this observation, it is,
therefore, accurate to state that if the drug is rapidly
distributed following its administration, regardless
of the route of administration, a one-compartment
model will do an adequate job of accurately and
adequately characterizing the plasma concentration
versus time data.
The terms rapid and slow distribution refer to
the time required to attain distribution equilibrium
for the drug in the body. The attainment of distribution equilibrium indicates that the rate of transfer
of drug from blood to various organs and tissues
and the rate of transfer of drug from various tissues
and organs back into the blood have become equal.
Therefore, rapid distribution simply suggests that the
rate of transfer of drug from blood to all organ and
tissues and back into blood have become equal instantaneously, following the administration (intra- or
extravascular) of the dose of a drug. Therefore, all
organs and tissues are behaving in similar fashion
toward the administered drug.
Slow distribution suggests that the distribution
equilibrium is attained slowly and at a finite time
(from several minutes to a few hours, depending upon
the nature of the administered drug). Furthermore,
it suggests that the vasculature, tissues, and organs
are not behaving in a similar fashion toward this drug
and, therefore, we consider the body to comprise two
compartments or, if necessary, more than two compartments.

Highly perfused systems, such as the liver and
the kidneys, may be pooled together with the blood

in one compartment (i.e., the central compartment:
compartment 1); and systems that are not highly perfused, such as bones, cartilage, fatty tissue, and many
others, can also be pooled together and placed in
another compartment (i.e., the tissue or peripheral
compartment: compartment 2). In this type of model,
the rates of drug transfer from compartment 1 to
compartment 2 and back to compartment 1 will become equal at a time greater than zero (from several
minutes to a few hours).
It is important to recognize that the selection
of the compartment model is contingent upon the
availability of plasma concentration versus time data.
Therefore, the model selection process is highly
dependent upon the following factors.
1 The frequency at which plasma samples are collected. It is highly recommended that plasma
samples are collected as early as possible, particularly for first couple of hours, following the
administration of the dose of a drug.
2 The sensitivity of the procedure employed to
analyze drug concentration in plasma samples.
(Since inflections of the plasma concentration
versus time curve in the low-concentration regions may not be detected when using assays
with poor sensitivity, the use of a more sensitive analytical procedure will increase the probability of choosing the correct compartment
model.)
3 The physicochemical properties (e.g., the
lipophilicity) of a drug.
As mentioned above, only the distribution characteristics of a drug play a role in the selection of the
compartment model. The chosen model, as well as
the route of drug administration, by comparison, will

contribute to the selection of an appropriate equation
necessary to characterize the plasma concentration
versus time data accurately. The following illustrations
and examples, hopefully, will delineate some of the
concepts discussed in this section.

Intravenous bolus administration,
one-compartment model
Figure 1.8 is a semilogarithmic (SL) plot of plasma
concentration versus time data for a drug administered as an intravenous bolus dose. A semilogarithmic plot derives its name from the fact that a single


9

Introduction and overview

Cp (μ g mL–1)

Cp (µ g mL–1)

Distribution or
α phase

Time (h)

Post-distribution or
β phase

Time (h)

Figure 1.8 A typical plot (semilogarithmic) of plasma
concentration (Cp ) versus time following the administration
of an intravenous bolus dose of a drug that is rapidly
distributed in the body.

Figure 1.9 A typical semilogarithmic plot of plasma
concentration (Cp ) versus time following the administration
of an intravenous bolus dose of a drug that is slowly
distributed in the body.

axis (the y-axis in this case) employs logarithmic coordinates, while the other axis (the x-axis) employs
linear coordinates. The plotted curve is a straight
line, which clearly indicates the presence of a single
pharmacokinetic phase (namely, the elimination
phase). Since the drug is administered intravenously,
there is no absorption phase. The straight line also
suggests that distribution is instantaneous; thus the
drug is rapidly distributed in the body. These data can
be accurately and adequately described by employing
the following monoexponential equation

straight line. The time at which the concentration
versus time plot begins to become a straight line
represents the occurrence of distribution equilibrium.
This suggests that drug is being distributed slowly
and requires a two-compartment model for accurate
characterization. The equation employed to characterize these plasma concentration versus time data
will be biexponential (i.e., contain two exponential
terms):

Cp = (Cp )0 e−Kt

(1.3)

where Cp is the plasma drug concentration at any time
t; and (Cp )0 is the plasma drug concentration at time
t = 0.
Note that there is a single phase in the concentration versus time plot and one exponential term in the
equation required to describe the data. This indicates
that a one-compartment model is appropriate in this
case.

Intravenous bolus administration,
two-compartment model
Figure 1.9 clearly shows the existence of two phases
in the concentration versus time data. The first phase
(curvilinear portion) represents drug distribution in
the body; and only after a finite time (indicated
by a discontinuous perpendicular line) do we see a

Cp = Ae−αt + Be−βt

(1.4)

where A and α are parameters associated with drug
distribution and B and β are parameters associated
with drug post-distribution phase.
Note that there are two phases in the concentration versus time data in Fig. 1.9 and that an
equation containing two exponential terms is required to describe the data. This indicates that a
two-compartment model is appropriate in this case.

Extravascular administration:
one-compartment model
The plasma concentration versus time profile presented in Fig. 1.10 represents a one-compartment
model for a drug administered extravascularly. There
are two phases in the profile: absorption and elimination. However, the profile clearly indicates the presence of only one phase in the post-absorption period.


10

Basic Pharmacokinetics

Absorption phase
Cp ( μg mL–1)

Cp (µ g mL–1)

Absorption phase

Elimination phase

Post-distribution
phase ( β phase)

Time (h)

Time (h)

Figure 1.10 A typical semilogarithmic plot of plasma
concentration (Cp ) versus time following the extravascular

administration of a dose of a drug that is rapidly distributed in
the body.

Since distribution is the sole property that determines
the chosen compartment model, and since the profile contains only one phase in the post-absorption
period, these data can be described accurately and
adequately by employing a one-compartment model.
However, a biexponential equation would be needed
to characterize the concentration versus time data
accurately. The following equation can be employed
to characterize the data:
Ka (Xa )t=0 −Kt
[e
− e−Ka t ]
V(Ka − K)
Ka FX0
[e−Kt − e−Ka t ]
=
V(Ka − K)

Distribution phase
( α phase)

Cp =

(1.5)

where Ka is the first-order absorption rate constant; K
is the first-order elimination rate constant; (Xa )t=0 is
the amount of absorbable drug at the absorption site

present at time zero; F is the absorbable fraction; and
X0 is the administered dose.
Please note that a one-compartment model will
provide an accurate description since there is only one
post-absorption phase; however, since there are two
phases for the plasma concentration versus time data,
a biexponential equation is required to describe the
data accurately.

Figure 1.11 A typical semilogarithmic plot of plasma
concentration (Cp ) versus time following the extravascular
administration of a dose of a drug that is slowly distributed in
the body.

for a drug administered by an extravascular route.
Three phases include absorption, distribution, and
post-distribution. Please note that in the figure, there
is a clear and recognizable distinction between the
distribution and post-distribution phases. Furthermore, the plasma concentration versus time profile,
in the post-absorption period, looks similar to that
for an intravenous bolus two-compartment model
(Fig. 1.9). These data, therefore, can be described
accurately by employing a two-compartment model
and the equation will contain three exponential terms
(one for each phase: absorption, distribution, and
post-distribution).
It should be stressed that these compartments do
not correspond to physiologically defined spaces (e.g.,
the liver is not a compartment).
If the chosen model does not adequately describe

the observed data (plasma concentration), another
model is proposed.
The model that is ultimately chosen should
always be the simplest possible model that is still
capable of providing an adequate description of the
observed data. The kinetic properties of a model
should always be understood if the model is used for
clinical predictions.

Types of model in pharmacokinetics
Extravascular route of drug
administration, two-compartment model
Figure 1.11 clearly shows the presence of three
phases in the plasma concentration versus time data

There are several types of models used:

•
•
•

one compartment
two compartments
three compartments or higher (not often used).